Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Conditions:  Gastrin-Producing Neuroendocrine Tumor;  Malignant Pancreatic Gastrinoma;  Malignant Pancreatic Glucagonoma;  Malignant Pancreatic Insulinoma;  Malignant Pancreatic Somatostatinoma;  Pancreatic Alpha Cell Adenoma;  Pancreatic Beta Cell Adenoma;  Pancreatic Delta Cell Adenoma;  Pancreatic G-Cell Adenoma;  Pancreatic Glucagonoma;  Pancreatic Insulinoma;  Pancreatic Polypeptide Tumor;  Recurrent Pancreatic Carcinoma;  Recurrent Pancreatic Neuroendocrine Carcinoma;  Somatostatin-Producing Neuroendocrine Tumor;  Stage III Pancreatic Cancer;  Stage IV Pancreatic CancerInterventions:  Drug: Everolimus;  Drug: Octreotide Acetate;  Biological: BevacizumabSponsor:  National Cancer Institute (NCI)Active, not recruiting - verified July 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Neurology | Neurosurgery | Pancreas | Pancreatic Cancer | Research | Sandostatin